BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly Strikes $870 Million Deal to Develop Long-Acting Obesity Treatments
Eli Lilly Strikes $870 Million Deal to Develop Long-Acting Obesity Treatments
12
1
U.S. pharmaceutical giant Eli Lilly & Co. has entered an $870 million collaboration with Sweden's Camurus to advance long-acting obesity therapies. The partnership leverages Camurus' FluidCrystal® drug delivery technology to enhance the durability of Lilly's weight-loss portfolio, including flagship injectable Zepbound.
The deal includes upfront and milestone payments, accelerating Lilly's push into extended-release formulations. This comes as the company develops an oral alternative to injectable weight-loss treatments, potentially expanding patient access.
By:
Previous
Inflation Expectations Ease as Economic Sentiment Improves
Next
Tesla Supercharger Closures in New Jersey Contrast with Share Price Resilience
